← Leaderboards
Charles Richard Esther
Univ Of North Carolina Chapel Hill
$2,865,620
Attributed
$4,934,614
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $692.8K · FY2009–23$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,084,614 · 4
FDA$850,000 · 1
By mechanism
R01$2,084,773 · 1
P01$1,089,623 · 1
U01$850,000 · 1
K23$685,260 · 1
R43$224,958 · 1
Top collaborators
- Marianne S Muhlebach4 shared
- Stephen Stick4 shared
- Martina Gentzsch3 shared
- Gauri G Rao3 shared
- Steven Isaacman1 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Michael Rubinstein$1,930,820
- Brian M Button$7,838,604
- Kathleen M Gray$3,997,180
- Ilona Jaspers$20,767,326
- William D Bennett$2,654,568
Others in their field
Top investigators on “Metabolomics”
- Jeffrey P Krischer · University Of South Florida$138,267,392
- Mine Cicek · Mayo Clinic Rochester$80,157,953
- Stephen Norman Thibodeau · Mayo Clinic Rochester$70,215,522
- Richard Gibbs · Baylor College Of Medicine$68,573,551
- Richard A Gibbs · Baylor College Of Medicine$62,998,471
- Leonardo Trasande · New York University School Of Medicine$57,546,121
Research focus
MetabolomicsCystic FibrosisSamplingExhalationMeasurementMucinsLungBaseMucous Body SubstanceLung DiseasesMass Spectrum AnalysisInfectionPrincipal InvestigatorInflammationSurfaceCell CountUreaSputumCohortChronicBiological MarkersInvestigationDehydrationChild
Grant awards (18)
A physiologically based pharmacokinetic model of human airway epithelia$250,000
U01 · FY2023 · FD · contact PI
A physiologically based pharmacokinetic model of human airway epithelia$300,000
U01 · FY2022 · FD · contact PI
A physiologically based pharmacokinetic model of human airway epithelia$300,000
U01 · FY2021 · FD · contact PI
Core D: Pharmacokinetics/Pharmacodynamics Core$212,435
P01 · FY2021 · HL · contact PI
Core D: Pharmacokinetics/Pharmacodynamics Core$238,672
P01 · FY2020 · HL · contact PI
Core D: Pharmacokinetics/Pharmacodynamics Core$161,172
P01 · FY2019 · HL · contact PI
Core D: Pharmacokinetics/Pharmacodynamics Core$238,672
P01 · FY2018 · HL · contact PI
Core D: Pharmacokinetics/Pharmacodynamics Core$238,672
P01 · FY2017 · HL · contact PI
A targeted drug for the treatment of inflammation in cystic fibrosis lung disease$224,958
R43 · FY2016 · HL
Mucus and hypoxia in heterogeneous and progressive CF lung disease$508,031
R01 · FY2015 · HL
Mucus and hypoxia in heterogeneous and progressive CF lung disease$513,438
R01 · FY2014 · HL
Mucus and hypoxia in heterogeneous and progressive CF lung disease$507,598
R01 · FY2013 · HL
Purines as Biomarkers of Respiratory Disease$137,052
K23 · FY2013 · HL · contact PI
Mucus and hypoxia in heterogeneous and progressive CF lung disease$555,706
R01 · FY2012 · HL
Purines as Biomarkers of Respiratory Disease$137,052
K23 · FY2012 · HL · contact PI
Purines as Biomarkers of Respiratory Disease$137,052
K23 · FY2011 · HL · contact PI
Purines as Biomarkers of Respiratory Disease$137,052
K23 · FY2010 · HL · contact PI
Purines as Biomarkers of Respiratory Disease$137,052
K23 · FY2009 · HL · contact PI